Data presented for the first time at the 29th Annual San Antonio Breast Cancer Symposium (SABCS) confirm that after five years of adjuvant breast cancer treatment, 'Arimidex' (anastrozole) performs ...

4th European Breast Cancer Conference - Hamburg, Germany. March 17 2004: New data presented today 1,2, indicate that preoperative (neoadjuvant) treatment with ARIMIDEX TM (anastrozole) results in ...

Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: an active regimen with limiting neurotoxicity. The median follow-up duration was approximately 6 months. The estimated ...

Women treated with Arimidex for five years were 50% less likely to have developed breast cancer recurrence compared with women given placebo at nearly 11 years follow-up after stopping treatment.

SAN ANTONIO — Anastrozole reduced breast cancer risk by 49% compared with placebo for postmenopausal women at high risk for the disease, according to long-term results of the randomized controlled ...

Two-thirds of breast tumours are oestrogen-receptor positive and 60–70% of these tumours respond to interventions that reduce the effects of oestrogen. Until recently, tamoxifen was the drug of choice ...

AstraZeneca this morning said that postmenopausal women taking the gold-standard tamoxifen for early breast cancer may significantly reduce their risk of recurrence by switching to the company’s new ...

The recent IBIS-II clinical trial results demonstrate anastrozole reduces breast cancer incidence by 53% in postmenopausal women. While this is a major advance in prevention research, its impact on ...

Women with a higher risk of developing breast cancer are set to be offered a pill that cuts their risk of developing the disease in half. NHS England and UK medication watchdogs announced the pill ...

Arimidex (anastrozole) is a prescription drug that’s taken to treat certain types of breast cancer in adults. The drug comes as a tablet that you swallow. It’s usually taken once per day. Specifically ...

-- The IBIS-II Prevention part of the study aims to recruit 6,000 postmenopausal women who are at increased risk of developing breast cancer. A number of factors for increased risk can make a woman ...